Gilead awards $4M funding to hepatitis B, C, D elimination projects
Gilead Sciences has awarded $4 million in funding via its ALL4LIVER grant program to organizations worldwide whose community-based efforts will help the World Health…
Hepatitis
Canada unlikely to hit 2030 hepatitis C elimination target: Study
Current screening and treatment strategies won’t allow Canada to eliminate new cases of hepatitis C by 2030, a population modeling study found. That’s the…
WHO: Despite advances in care, deaths from hepatitis increasing
Technologies to prevent, detect, and treat viral hepatitis have advanced considerably in recent decades, but the number of people dying from these infections continues…
FDA expands Vemlidy to chronic hepatitis B patients as young as 6
The U.S. Food and Drug Administration (FDA) has again expanded its approval of Gilead Sciences’ medication Vemlidy (tenofovir alafenamide) for chronic hepatitis B…
Triple natural hepatitis C clearance case may aid vaccine development
Researchers have identified new strategies for developing a vaccine against hepatitis C by studying the immune responses of a patient who spontaneously cleared three…
US centers get $2.1M to help hepatitis patients find doctors
The Center for Disease Analysis (CDA) Foundation has granted $2.1 million in funding to 14 U.S. organizations to help diagnosed but untreated hepatitis…
Atea’s antiviral treatment combo works for 98% of HCV patients
Note: This story was updated Aug. 22, 2024, to clarify the timeline detailing the results of treatment. Atea Pharmaceuticals’ once-daily oral antiviral treatment for…
Many viruses behind 2022 outbreak of hepatitis in children: Study
A global outbreak of severe hepatitis in children just after COVID-19 restrictions were lifted could have been caused by infections with multiple viruses at…
Many patients face barriers in accessing treatments for hepatitis C
While highly effective treatments for hepatitis C are available worldwide, many people — especially those living in poorer countries — are not able to access…
GSK’s hepatitis B candidate bepirovirsen wins fast track status
The U.S. Food and Drug Administration (FDA) has granted fast track status to bepirovirsen, GlaxoSmithKline (GSK)’s candidate treatment for chronic hepatitis B (CHB),…
Recent Posts
- Rezdiffra reduces scarring in MASH with compensated cirrhosis: Trial
- 6 JAG1, NOTCH2 gene mutations ID’d as likely cause of Alagille
- To test or not to test for PFIC3? Our families face the question.
- Hepatitis C telemedicine approach for opioid users receives award
- Seladelpar conditionally approved in European Union to help treat PBC